Mupirocin, fusidic acid and bacitracin: Activity, action and clinical uses of three topical antibiotics

Veterinary Dermatology

Volumn 10, Issue 3, 1999, Pages 225-240

  Werner, Alexander H ^a   Russell, A Denver ^b  

^a Veterinary Specialty Services   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Acne; Bacitracin; Cat; Dog; Fusidic acid; Mupirocin; Pyoderma; Topical antibiotics

Indexed keywords

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 0033455664     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3164.1999.00185.x     Document Type: Article

References (172)

1. Walton, J.R. Use of antibiotics in veterinary practice. Journal of Medical Microbiology 1992; 36: 69-70.
2. Greenwood, D. (ed.) Antimicrobial Chemotherapy, 3rd edn. Oxford: Oxford University Press: 1994.
3. Kucers, A., Gowe, S.M., Grayson, M.L., Hoy, J.F. Use of Antibiotics - a Clinical Review of Antibacterial, Antifungal and Antiviral Drugs, 5th edn. Oxford: Butterworth Heinemann: 1997. pp. 542, 546, 584-5.
4. Anonymous. ABPI Data Sheet Compendium, London: Datapharm Publications Ltd: Year?
5. Compendium of Data Sheets for Veterinary Products. Enfield: National Office of Animal Health Ltd. 1998-99.
6. British National Formulary (BNF.), Number 32. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain: 1999.
7. Arrioja-Dechere, A. (ed) Compendium of Veterinary Products, 4th edn. Port Huran: North American Compendiums, Inc: 1997-98.
8. Bishop, Y. (ed.) The Veterinary Formulary. 4th edn. London: The Pharmaceutical Press, 1998: 454-57.
9. Russell, A.D., Day, M.J. Antimicrobial activity of chlorhexidine. Journal of Hospital Infection, 1993; 25: 229-38.
10. Hugo, W.B., Russell, A.D. Types of antimicrobial agents. In: Russell, A.D., Hugo, W.B., Ayliffe, G.A.J. eds. Principles and Practice of Disinfection, Preservation and Sterilization. 3rd edn. Oxford: Blackwell Science, 1999: 5-94.
11. Russell, A.D., Hugo, W.B., Aylifie, G.A.J., eds. Principles and Practice of Disinfection, Preservation and Sterilization, 3rd edn. Oxford: Blackwell Science 1999.
12. Ward, A., Campoli-Richards, D.M. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986; 32: 425-44.
13. Gratton, D. The use of topical antibiotics. Contemporary Dermatology, 1987; 1: 3-7.
14. Slack, R.C.B. Topical use of antimicrobial agents. In: Greenwood, D. ed. Antimicrobial Chemotherapy, 2nd edn. Oxford: Oxford University Press, 1989: 333-41.
15. Eady, E.A., Cove, J.H. Topical antibiotic therapy: current status and future prospects. Drugs in Experimental Clinical Research, 1990; 16: 423-33.
16. Hirschmann, J.V. Topical antibiotics in dermatology. Archives of Dermatology 1988; 124: 1691-700.
17. Parenti, M.A., Hatfield, S.M., Leyden, J.J. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clinical Pharmacy 1987; 6: 761-70.
18. Noble, W.C. Choice of topical antibiotics: a microbiological viewpoint. Clinical and Experimental Dermatology, 1981; 6: 503-7.
19. Noble, W.C. Staphylococci on the skin. In: Noble, W.C. ed. Skin Microflora and Microbial Skin Disease. Cambridge: Cambridge University Press, 1992: 135-52.
20. Noble, W.C. Staphylococcal diseases. In: Hausler, W. Jr, Sussman, M. eds. Topley and Wilson's Microbiology and Microbial Infections 9th edn, Vol. 3, Bacterial Infections. London: Arnold, 1998: 231-56.
21. Noble, W.C. Skin bacteriology and the role of Staphylococcus aureus in infection. British Journal of Dermatology 1998; 139(Suppl. 53): 9-12.
22. French, G.L., Phillips, I. In: O'Grady, F., Lambert, H.P., Finch, R.G., Greenwood, D., eds. Resistance in Antibiotic and Chemotherapy: Anti-Infective Agents and Their Use in Therapy. 7th edn. Edinburgh: Churchill Livingstone, 1997: 23-43.
23. Cox, H.U., Newman, S.S., Roy, A.F., Hoskins, J.D. Species of Staphylococcus isolated from animal infection. Cornell Veterinarian 1984; 74: 124-35.
24. Allaker, R.P., Lloyd, D.H., Bailey, R.M. Population sites and frequency of staphylococci at mucocutaneous sites on healthy dogs. Veterinary Record 1992; 130: 303-1.
25. Allaker, R.P., Lloyd, D.H., Simpson, A.I. Occurrence of Staphylococcus intermedius on the hair and skins of normal dogs. Research in Veterinary Science, 1992; 52: 174-6.
26. Allaker, R.P., Garrett, N., Kent, L., Noble, W.C., Lloyd, D.H. Characterisation of Staphylococcus intermedius isolates from cases of canine pyoderma and healthy carriers by SDS-PAGE of exoproteins, immunoblotting and restriction-endonuclease analysis. Journal of Medical Microbiology 1993; 39: 429-43.
27. White, S.D. Systemic treatment of bacterial skin infections of dogs and cats. Veterinary Dermatology 1996; 7: 133-43.
28. Devriese, L.A., De Pelsmaecker, K. The anal region as a main carrier site of Staphylococcus intermedius and Streptococcus canis in dogs. Veterinary Record, 1987; 121: 302-3.
29. Cree, R.G.A., Noble, W.C. In vitro indices of tissue adherence in Staphylococcus intermedius. Letters in Applied Microbiology 1995; 20: 168-70.
30. Saijonmaa-Koulumies, L.E., Parsons, E., Lloyd, D.H. Elimination of Staphylococcus intermedius in healthy dogs by topical treatment with fusidic acid. Journal of Small Animal Practice, 1998; 39: 341-7.
31. Mason, I. Selection and use of antibacterial agents in canine pyoderma. In Practice 1993 (May): 129-34.
32. Berg, J.N., Wendell, D.E., Vogelweid, C., Fales, W.H. Identification of the major coagulase-positive Staphylococcus sp. of dogs as Staphylococcus intermedius. American Journal of Veterinary Research 1984; 45: 1307-9.
33. Lilenbaum, W., Nunes, E.L.C., Azerado, M.A.I. Prevalence and antimicrobial susceptibility of staphylococci isolated from the skin surface of clinically normal cats. Letters in Applied Microbiology 1998; 27: 224-8.
34. Saijonmaa-Koulumies, L., Lloyd, D.H. Colonisation of the canine skin with bacteria. Veterinary Dermatology 1996; 7: 153-62.
35. Ihrke, P.J. An overview of bacterial skin disease in the dog. British Veterinary Journal 1987; 143: 112-8.
36. Medleau, L., Long, R.E., Brown, J., Miller, W.H. Frequency and antimicrobial susceptibility of Staphylococcus species isolated from canine pyodermas. American Journal of Veterinary Research 1986; 47: 229-31.
37. Harvey, R.G., Noble, W.C. Aspects of nasal, oropharyngeal and anal carriage of Staphylococcus intermedius in normal dogs and dogs with pyoderma. Veterinary Dermatology 1998; 9: 99-104.
38. Harvey, R.G., Lloyd, D.H. The distribution of Staphylococcus intermedius and coagulase-negative staphylococci on the hair, skin surface, within the hair follicles, and on the mucous membranes of dogs. Veterinary Dermatology 1994; 5(2): 75-81.
39. Harvey, R.G., Noble, W.C. A temporal study comparing the carriage of Staphylococcus intermedius on normal dogs with atopic dermatitis in remission. Veterinary Dermatology 1994; 5: 21-5.
40. Mason, I.S., Mason, K.V., Lloyd, D.H. A review of the biology of canine skin with respect to the commensals Staphylococcus intermedius, Demodex canis, and Malassezia pachydermatis. Veterinary Dermatology 1996; 7: 119-32.
41. Allaker, R.P., Lloyd, D.H., Bailey, R.M. Population sizes and frequency of staphylococci at mucocutaneous sites on healthy dogs. Veterinary Record 1992; 130: 303-4.
42. Oluoch, A.O., Weisiger, R., Siegel, A.M., Campbell, K.L., Krawiec, D.R., McKiernan, B.C., Kakoma, I. Trends of bacterial infections in dogs; characterization of Staphylococcus intermedius isolates (1990-92). Canine Practice 1996; 21: 12-9.
43. Mason, I.S., Lloyd, D.H. The role of allergy in the development of canine pyoderma. Journal of Small Animal Practice 1992; 30: 216-8.
44. Kristensen, S., Krogh, H.V. A study of skin disease in dogs and cats. III. Microflora of the skin of dogs with chronic eczema. Nordisk Veterinaermedicin 1978; 30: 223-30.
45. Toyoda, M., Morohashi, M. An overview of topical antibiotics for acne treatment. Dermatology 1998; 196: 130-4.
46. Goodacre, R., Neal, M.J., Kell, D.B., Greenham, L.W., Noble, W.C., Harvey, R.G. Rapid identification using pyrolysis mass spectrometry and artificial neural networks of Propionibacterium acnes isolated from dogs. Journal of Applied Bacteriology 1994; 76: 124-34.
47. Goodacre, R., Harvey, R., Howell, S.A., Greenham, L.W., Noble, W.C. An epidemiological study of Staphylococcus intermedius strains isolated from dogs, their owners and veterinary surgeons. Journal of Analytical and Applied Pyrolysis 1997; 44: 49-64.
48. Talan, D.A., Staatz, A., Goldstein, E.J.C., Singer, K., Overturf, G.D. Staphylococcus intermedius in canine gingiva and canine-inflicted human wounds: laboratory characterisation of a newly recognised zoonotic pathogen. Journal of Clinical Microbiology 1989; 27: 78-81.
49. Naidoo, J., Lloyd, D.H. Transmission of genes between staphylococci on skin. In: Woodbine, M. ed. Antimicrobials and Agriculture. London: Butterworth, 1984: 285-92.
50. Keane, K.A., Taylor, D.J. Slime-producing Staphylococcus species in canine pyoderma. Veterinary Record 1992; 130: 75.
51. Darmstadt, G.L., Lane, A.T. Impetigo: an overview. Pediatric Dermatology 1994; 11: 293-303.
52. Feingold, D.S. Bacterial adherence, colonization and pathogenicity. Archives of Dermatology 1986; 122: 161-3.
53. Pedersen, K., Wegener, H.C. Antimicrobial susceptibility and rRNA gene restriction patterns among Staphylococcus intermedius from healthy dogs and from dogs suffering from pyoderma or otitis externa. Acta Veterinaria Scandinavica 1995; 36: 335-42.
54. Arigoni, D., von Daehne, W., Godtfredsen, W.O., Melera, A., Vangedal, S. The stereochemistry of fusidic acid. Experientia, 1964; 20: 344-7.
55. Anonymous. Martindale, The Extra Pharmacopoeia, 30th edn. London: Pharmaceutical Press. 1999.
56. Barber, M., Watenvorth, P.M. Antibacterial activity in vitro of Fucidin. Lancet 1962; i: 932-3.
57. Hilson, G.R.F. In vitro studies on a new antibiotic (Fucidin). Lancet 1962; i: 932-3.
58. Evans, R.J., Waterworth, P.M. Naturally-occurring fusidic acid resistance in staphylococci and its linkage to other resistances. Journal of Clinical Pathology 1966; 19: 555-60.
59. Verbist, L. The antimicrobial activity of fusidic acid. Journal of Antimicrobial Chemotherapy 1990; 25(Suppl. B): 1-5.
60. Faber, M., Rosdahl, V.T. Susceptibility to fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption. Journal of Antimicrobial Chemotherapy 1990; 25(Suppl. B): 7-14.
61. Shanson, D.C. Clinical relevance of resistance to fusidic acid in Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 1990; 25(Suppl. B): 15-21.
62. Marsh, B. Fusidic acid: versatile and still effective. Mims Magazine 1999 (15 November issue): 52-3.
63. Tanaka, H., Kinoshita, T., Masukawa, H. Mechanism of protein synthesis inhibition by fusidic acid and related antibiotics. Biochemical and Biophysical Research Communications 1968; 30: 278-83.
64. Russell, A.D., Chopra, I. Understanding Antibacterial Action and Resistance, 2nd edn. Chichester: Ellis Horwood 1996.
65. Yamaki, H. Inhibition of protein synthesis by fusidic and helvolinic acids, steroidal antibiotics. Journal of Antibiotics, Series A 1965; XVII: 228-32.
66. Prehn, K., Tybring, L., Forchhammer, J. Fusidic acid and derivatives. Inhibition of protein synthesis in cell-free systems from Escherichia coli and Bacillus stearothermophilus. Acta Pathologica et Microbiologica Scandinavia 1967; 71: 135-40.
67. Chopra, I. Mechanisms of resistance to fusidic acid in Staphylococcus aureus. Journal of General Microbiology 1976; 96: 229-38.
68. Lacey, R.W. Treatment of staphylococcal infections. Journal of Antimicrobial Chemotherapy 1863; 11: 3-6.
69. Volker, T.A., Iida, S., Bickle, T.A. A single gene coding for resistance to both fusidic acid and chloramphenicol. Journal of Molecular Biology, 1982; 154: 417-25.
70. Everett, S.L., Kowalski, R.P., Karenchak, I.M., Landsittel, D., Day, R., Gordon, Y.J. An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea 1995; 14: 382-7.
71. Kruse, H., Hofshagen, M., Thoresen, S.I., Bredel, W.P., Vollset, I., Soli, N.E. The antimicrobial susceptibility of Staphylococcus species isolated from canine dermatitis. Veterinary Research Communications, 1996; 20: 205-14.
72. Thestrup-Pedersen, K. Bacteria and the skin: clinical practice and therapy update. British Journal of Dermatology 1998; 139(Suppl. 53): 1-3.
73. Espersen, F. Resistance to antibiotics used in dermatological practice. British Journal of Dermatology 1998; 139(Suppl. 53): 4-8.
74. Abeck, D., Mempel, M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. British Journal of Dermatology 1998; 139(Suppl. 53): 13-6.
75. Wilkinson, J.D. Fusidic acid in dermatology. British Journal of Dermatology 1998; 139(Suppl. 53): 37-40.
76. Morgan, M., Salmon, R., Keppie, N., Evans-Williams, D., Hosein, I., Looker, D.N. All Wales surveillance of methicillin-resistant Staphylococcal aureus (MRSA): the first year's results. Journal of Hospital Infection 1999; 41: 173-9.
77. Reeves, D.S. The pharmacokinetics of fusidic acid. Journal of Antimicrobial Chemotherapy 1987; 20: 467-76.
78. Hansen, S. Intraocular penetration of fusidic acid with topical Fucithalmic. European Journal of Drug Metabolism and Pharmacokinetics 1985; 10: 329-31.
79. Pott, M. The pharmacology of fusidic acid - the antimicrobial component of a new viscous drop topical ophthalmic formulation for dogs. Journal of the British Association of Veterinary Ophthalmologists 1994 issue 6.
80. Vickers, C.F.H. Percutaneous absorption of sodium fusidate and fusidic acid. British Journal of Dermatology 1969; 81: 902-8.
81. Knight, A.G., Vickers, C.F.H., Percival, A. The percutaneous absorption of antibacterial substances. British Journal of Dermatology 1969; 81(Suppl.): 88-90.
82. Stüttgen, G., Bauer, E. Penetration and permeation into human skin of fusidic acid in different galenical formulation. Arzneimittel-Forschung Drug Research, 1988; 38: 730-5.
83. Sutherland, R., Boon, R.J., Griffin, K.E., Masters, P.J., Slocombe, B., White, A.R. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for future use. Antimicrobial Agents and Chemotherapy 1985; 27: 495-8.
84. Wilkinson, D.S., Price, J.D., eds. Mupirocin - a Novel Topical Antibiotic. London: Royal Society of Medicine 1984.
85. Dobson, R.L., Leyden, J.J., Noble, W.C., Price, J.D., eds. Bactroban (Mupirocin). Amsterdam: Excerpta Medica 1985.
86. Casewell, M.W., Hill, R.L.R. In vitro activity of mupirocin (pseudomonic acid) against clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 1985; 15: 523-31.
87. Hughes, J., Mellows, G. On the mode of action of pseudomonic acid: inhibition of protein synthesis of Staphylococcus aureus. Journal of Antibiotics, 1978; 31: 330-5.
88. Hughes, J., Mellows, G. Inhibition of isoleucyl-transfer ribonucleic acid synthebase in Escherichia coli by pseudomonic acid. Biochemical Journal 1978; 176: 305-18.
89. Hughes, J., Mellows, G. Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthebase. Biochemical Journal 1980; 191: 209-19.
90. Casewell, M.W., Hill, R.L.R. Murirocin ('pseudomonic acid') - a promising new topical antimicrobial agent. Journal of Antimicrobial Chemotherapy 1987; 19: 1-5.
91. Evans, L.H., Townsend, D.E. Mupirocin activity against methicillin-resistant Staphylococcus aureus. Medical Journal of Australia 1986; 145: 55-6.
92. Rode, H., de Wet, P.M., Millar, A.J.W., Cywes, S. Efficacy of mupirocin in cutaneous candidiasis. Lancet, 1991; 338: 578.
93. Chapnick, E.K., Gradon, J.D., Kreiswirth, B., Lutwick, L.J., Schaffer, B.C., Schiano, T.D., Levi, M.H. Comparative killing kinetics of methicillin-resistant Staphylococcus aureus by bacitracin or mupirocin. Infection Control and Hospital Epidermiology 1996; 17: 178-80.
94. Thomas, W.G., Wilson, J.M., Day, M.J., Russell, A.D. Mupirocin resistance in staphylococci: development and transfer of isoleucyl tRNA synthebase-mediated resistance in vitro. Journal of Applied Microbiology 1999; 86: 715-722.
95. Vaera, M. The outer membrane as the penetration barrier against mupirocin in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy 1992; 29: 221-2.
96. Al-Masaudi, S.B., Russell, A.D., Day, M.J. Activity of mupirocin against Staphylococcus aureus and outer. membrane mutants of Gram-negative bacteria. Letters in Applied Microbiology 1988; 7: 45-7.
97. Rahman, M., Noble, W.C., Cookson, B. Mupirocin-resistant Staphylococcus aureus. Lancet 1987; 2: 287.
98. Baird, D., Coia, J. Mupirocin-resistant Staphylococcus aureus. Lancet 1987; 2: 387-8.
99. Kavi, J., Andrew, J.M., Wise, R. Mupirocin-resistant Staphylococcus aureus, Lancet 1987; 2: 1472.
100. Smith, M.D., Sanghrajka, M., Lock, S. Mupirocin-resistant Staphylococcus aureus. Lancet 1987; 2: 1472-3.
101. Cookson, B.D. Mupirocin resistance in staphylococci. Journal of Antimicrobial Chemotherapy 1990; 25: 497-503.
102. Hudson, I. Mupirocin resistant Staphylococcus aureus. Lancet, 1992; 339: 56.
103. Cookson, B., Barrelly, H., Palepou, M.F., George, F. Mupirocin-resistant Staphylococcus aureus. Lancet, 1992; 339: 625.
104. Cookson, B.D. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. Journal of Antimicrobial Chemotherapy 1998; 41: 11-8.
105. Noble, W.C., Rahman, M., Cookson, B.D., Phillips, I. Transferable mupirocin resistance. Journal of Antimicrobial Chemotherapy 1988; 22: 771-2.
106. Capobianco, J.M., Doran, C.C., Gollman, R.C. Mechanism of mupirocin transport into sensitive and resistant bacteria. Antimicrobial Agents and Chemotherapy, 1989; 33: 154-63.
107. Rahman, M., Noble, W.C., Cookson, B.D. Transmissible mupirocin resistance in Staphylococcus aureus. Epidemiology and Infection, 1989; 102: 261-70.
108. Rahman, M., Connolly, S., Noble, W.C., Cookson, B.D., Phillips, I. Diversity of staphylococci exhibiting high-level resistance to mupirocin. Journal of Medical Microbiology, 1990; 33: 91-100.
109. Al-Masaudi, S.B., Day, M.J., Russell, A.D. Antibacterial resistance and gene transfer in Staphylococcus aureus. Journal of Applied Bacteriology 1991; 70: 279-90.
110. Farmer, T.H., Gilbart, J., Elson, J.W. The biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 1992; 30: 587-96.
111. Gilbart, J., Perry, C.R., Slocombe, B. High level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl tRNA synthetases. Antimicrobial Agents and Chemotherapy 1993; 37: 32-8.
112. Rahman, M., Noble, W.C., Dyke, K.G.H. Probes for the study of mupirocin resistance in staphylococci. Journal of Medical Microbiology 1993; 39: 446-9.
113. Antonio, M., Ward, J.M., Pallen, M.J. Molecular basis of moderate-level mupirocin resistance in hospital isolates of methicillin-resistant Staphylococcus aureus. Proceedings of the Society for General Microbiology 1995 Abstract P84.
114. Baines, P.J., Jackson, D., Mellows, G., Swisland, A.J., Tasker, T.C.G. Mupirocin: its chemistry and metabolism. In: Wilkinson, D.S., Price, J.D. eds. Mupirocin - a Novel Topical Antibiotic. London: Royal Society of Medicine, 1984: 13-22.
115. Cockburn, A., Jackson, D., White, D.J. The background of the safety and tolerance of mupirocin. In: Dobson, R.L., Leyden, J.J., Noble, W.C., Price, J.D. eds. Bactroban (Mupirocin). Amsterdam: Excerpta Medical, 1985: 11-8.
116. Kaczmarski, E.B. Mupirocin in polyethylene glycol base is not suitable for application to burns. Journal of Antimicrobial Chemotherapy 1988; 21: 771-6.
117. Boon, R.J., Beale, A.S., Sutherland, R. Efficacy of topical mupirocin against an experimental Staphylococcus auretis surgical wound infection. Journal of Antimicrobial Chemotherapy 1985; 16: 519-26.
118. Casewell, M.W., Hill, R.L.R. Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid') - a controlled trial. Journal of Antimicrobial Chemotherapy 1986; 17: 365-72.
119. Hill, R.L.R., Duckworth, G.J., Casewell, M.W. Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak. Journal of Antimicrobial Chemotherapy 1988; 22: 377-84.
120. Kaufman, C.A., Terpenning, M.S., He, X., Tarins, L.T., Ramsey, M.A., Jorgensen, K.A., Sottile, W.S., Bradley, S.F. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. American Journal of Medicine 1993; 94: 371-8.
121. Irish, D., Eleringham, I., Teall, A., Pickett, H., Farelly, H., Reith, S., Woodford, N., Cookson, B. Control of an outbreak of epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. Journal of Hospital Infection 1998; 39: 19-26.
122. Anonymous. Bacitracin: A Review and Digest of the Literature Up to and Including January 1952. New York: S B Penick & Company, 1952.
123. Siewert, G., Strominger, G.L. Bacitracin: an inhibitor of the dephosphorylation of lipid pyrophosphate, an intermediate in biosynthesis of the peptidoglycan of bacterial cell Walls. Proceedings of the National Academy of Sciences, USA 1967; 57: 767-73.
124. Adler, R.H., Snoke, J.E. Requirements of divalent metal ions for bacitracin activity. Journal of Bacteriology 1962; 83: 1315-7.
125. Smith, J.L., Weinberg, E.D. Mechanisms of antibacterial action of bacitracin. Journal of General Microbiology 1962; 28: 559-69.
126. Hancock, R., Fitz-James, P.C. Some differences in the action of penicillin, bacitracin and vancomycin on Bacillus megaterium. Journal of Bacteriology 1964; 87: 1044-50.
127. Snoke, J.E., Cornell, N. Protoplast lysis and inhibition of growth of Bacillus licheniformis by bacitracin. Journal of Bacteriology 1965; 89: 415-20.
128. Storm, D.R. Mechanism of bacitracin action: a specific lipid-peptide interaction. Annals of the New York Academy of Science 1974; 235: 387-98.
129. Hendley, J.O., Ashe, K.M. Effect of topical antimicrobial treatment on aerobic bacteria in the stratum corneum of human skin. Antimicrobial Agents and Chemotherapy 1991; 35: 627-31.
130. Katz, B.E., Fisher, A.A. Bacitracin: a unique topical antibiotic sensitizer. Journal of the American Academy of Dermatology 1987; 17: 1016-24.
131. Christensen, O.B., Anehus, S.I.W. Hydrogen peroxide cream: an alternative to topical antibiotics in the treatment of impetigo contagiosa. Acta Dermato-Venereologica 1994; 74: 460-2.
132. Hamann, K., Thorn, P. Systemic or local treatment of erythrasma? A comparison between erythromycin tablets and fucidin cream in general practice. Scandinavian Journal of Primary Health Care 1991; 9: 35-9.
133. Pakrooh, H. A comparison of sodium fusidate ointment ('Fucidin') alone versus oral antibiotic therapy in soft-tissue infections. Current Medical Research and Opinion 1978; 5: 289-94.
134. Hedstrom, S.A. Treatment and prevention of recurrent staphylococcal furunculosis: clinical and bacteriological follow-up. Scandinavian Journal of Infections Diseases 1985; 17: 55-8.
135. Hjorth, N., Schmidt, H., Thomsen, K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126-31.
136. Ramsay, C.A., Savoie, J.M., Gilbert, M., Gidon, M., Kidson, P. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology 1996; 7: S15-22.
137. Schroeder, H., Swan, G.E., Berry, W.L., Pearson, J. Efficacy of a topical antimicrobial-anti-inflammatory combination in the treatment of pyotraumatic dermatitis in dogs. Veterinary Dermatology 1996; 7: 163-70.
138. Gratton, D. The use of topical antibiotics. Contemporary Dermatology 1987; 1: 3-7.
139. Morley, P.A.R., Munot, L.D. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Current Medical Research and Opinion 1988; 11: 142-8.
140. Veien, N.K. The clinician's choice of antibiotics in the treatment of bacterial skin infection. British Journal of Dermatology 1998; 139: 30-6.
141. White, D.G., Collins, P.O., Rowsell, B. Topical antibiotics in the treatment of superficial skin infections in general practice - a comparison of mupirocin with sodium fusidate. Journal of Infection 1989; 18: 221-9.
142. Gilbert, M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. Journal of the American Academy of Dermatology 1989; 20: 1083-7.
143. Lewis-Jones, S., Hart, C.A., Vickers, C.F.H. Bactroban ointment versus fusidic acid in acute primary skin infections in children. In: Dobson, R.L., Leyden, J.J., Noble, W.C., Price, J.D. eds. Bactroban (Mupirocin). Proceedings of an International Symposium. Amsterdam: Excerpta Medica; Current Clinical Practice Series, 16 1985: 103.
144. El Ferghani, N. An open study of mupirocin in Libyan patients with skin infections. Journal of International Medical Research 1995; 23: 508-17.
145. Leyden, J.J., James, W.D. Staphylococcus aureus infection as a complication of isotretinoin therapy. Archives of Dermatology 1987; 123: 606-8.
146. Dagan, R., Bar-David, Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrobial Agents and Chemotherapy 1992; 36: 287-90.
147. Goldfarb, J., Crenshaw, D., O'horo, J., Lemon, E., Blumer, J.L. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrobial Agents and Chemotherapy 1988; 32: 1780-3.
148. McLinn, S. Topical mupirocin versus systemic erythromycin treatment for pyoderma. Pediatric Infections Disease Journal 1988; 7: 785-90.
149. Raz, R., Miron, D., Colodner, R., Staler, Z., Samara, Z., Keness, Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Archives of Internal Medicine 1996; 156: 1109-12.
150. Perl, T.M., Golub, J.E. New approaches to reduce Staphylococcus aureus nosocomial infection rates: Treating S. aureus nasal carriage. Annals of Pharmacotherapy 1998; 32: S7-16.
151. Lamb, Y. J. Overview of the role of mupirocin. Journal of Hospital Infection 1991; 19: S27-30.
152. Doebbeling, R.N., Reagan, D.R., Pfaller, M.A., Houston, A.K., Hollis, R.J., Wenzel, R.P. Long term efficacy of intranasal mupirocin ointment. Archives of Internal Medicine 1994; 154: 1505-7.
153. Bertino, J.S. Jr. Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. American Journal of Health-System Pharmacy 1997; 54: 2185-91.
154. Casewell, M.W., Hill, R.J.R. Elimination of nasal carriage of Staphylococcus aureus with mupirocin (pseudomonic acid) - a controlled trial. Journal of Antimicrobial Chemotherapy 1986; 17: 365-72.
155. Guaguere, E. Topical treatment of canine and feline pyoderma. Veterinary Dermatology 1996; 7: 145-51.
156. White, S.D., Bordeau, P.B., Blumstein, P., Ibisch, C., Guaguere, E., Denerolle, P., Carlotti, D.N., Scott, K.V. Feline acne and results of treatment with mupirocin in an open clinical trial: 25 cases (1994-96). Veterinary Dermatology 1997; 8: 157-64.
157. Chapnick, E.K., Gradon, J.D., Kreiswirth, B., Lutwick, L.I., Schaffer, B.C., Schiano, T.D., Levi, M.H. Comparative killing kinetics of methicillin-resistant Staphylococcus aureus by bacitracin or mupirocin. Infection Control and Hospital Epidemiology 1996; 17: 178-80.
158. Smack, D.P., Harrington, A.C., Dunn, C., Howard, R.S., Szkutnik, A.J., Krivda, S.J., Caldwell, J.B., James, W.D. Infection and allergy incidence in ambulatory surgery patients using white petrolatum versus bacitracin ointment: a randomized controlled trial. Journal of the American Medical Association 1996; 276: 972-7.
159. Bass, J.W., Chan, D.S., Creamer, K.M., Thompson, M.W., Malone, F.J., Becker, T.M., Marks, S.N. Comparison of oral cephalexin, topical mupirocin, and topical bacitracin for treatment of impetigo. Pediatric Infectious Disease Journal 1997; 16: 708-10.
160. Miller, Y.W., Eady, E.A., Lacey, R.W., Cove, J.H., Joanes, D.N., Cunliffe, W.J. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. Journal of Antimicrobial Chemotherapy 1996; 38: 829-37.
161. Pellerin, J.L., Bourdeau, P., Sebbag, H., Person, J.M. Epidemiosurveillance of antimicrobial compound resistance of Staphylococcus intermedius clinical isolates from canine pyodermas. Comparative Immunology, Microbiology and Infectious Diseases 1998; 21: 115-33.
162. Zakrzewska-Bode, A., Muytjens, H.L., Liem, K.D., Hoogkamp-Korstanje, J.A.A. Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. Journal of Hospital Infection 1995; 31: 189-93.
163. Shelanski, M.V., Phillips, S.B., Potts, C.E. Evaluation of cutaneous reactivity to recently marketed dermatologic products. International Journal of Dermatology 1996; 35: 137-40.
164. Leyden, J.J., Kligman, A.M. Contact dermatitis to neomycin sulfate. Journal of the American Medical Association 1979; 242: 1276-8.
165. Kim, C.H., Oh, Y.S., Hong, S.H., Kye, Y.C., Moon, K.C. Two cases of allergic contact dermatitis to sodium fusidate. Korean Journal of Dermatology 1993; 31: 944-7.
166. El-Kassar, N., Kalfon, P., Fromont, P., Vezinet, C., Godeau, B., Duedari, N., Bierling, P. Fusidic acid induced acute immunologic thrombocytopenia. British Journal of Haematology 1996; 93: 427-31.
167. Zappi, E.G., Brancaccio, R.R. Allergic contact dermatitis from mupirocin ointment. Journal of the American Academy of Dermatology 1997; 36: 266.
168. Leyden, J.J. Double-blind vehicle-controlled studies of Bactroban ointment in secondary infections. In: Dobson, R.L., Leyden, J.J., Noble, W.C., Price, J.D. eds. Bactroban (Mupirocin). Proceedings of an International Symposium. Amsterdam: Excerpta Medica; Current Clinical Practice Series, 16, 1985: 183-9.
169. Schechter, J.R., Wilkinson, R.D., Carpio, J.D. Anaphylaxis following the use of bacitracin ointment. Archives of Dermatology 1984; 120: 909-11.
170. Fisher, A.A. Lasers and allergic contact dermatitis to topical antibiotics, with particular reference to bacitracin. Cutis 1996; 58: 252-4.
171. Sutton, J.B., Langdon, C.G. An analysis of the cost effectiveness of fusidic acid cream and mupirocin ointment in the treatment of superficial skin sepsis in general practice. British Journal of Medical Economics 1993; 6: 37-43.
172. Saijonmaa-Koulumies, L.E., Lloyd, D.H. Carriage of bacteria antagonistic towards Staphylococcus intermedius on canine skin and mucosal surfaces. Veterinary Dermatology 1995; 6: 187-94.